MedWatch

Novo CSO welcomes rival's success

In recent studies, Eli Lilly showed promising data for two candidates that are to ensure the US drug group success at the crucial GLP-1 market. CSO in Novo Nordisk, Mads Krogsgaard Thomsen, also consider the rival's results a positive development for the Danish drug group. "A happy and innovative competitor is the best," he says and stresses that Novo can still make a countermove.

Foto: /Ritzau Scanpix/Claus Bech

In the past month, US drug group Eli Lilly has showed positive data from two clinical trials with diabetes drugs. The results might influence the rival Novo Nordisk's future opportunities in the most critical segment of the diabetes market: treatment of type 2 diabetes with GLP-1-based medicines.

However, CSO in Novo Nordisk, Mads Krogsgaard Thomsen, is not worried.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier